Memory Pharmaceuticals Highlights Progress with Key Programs at i...(ependence on preclinical and clinical in...),Health

Date:5/16/2008

ependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain listing on the Nasdaq Global Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

'/>"/>

SOURCE Memory Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
2. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
3. Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease
4. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
5. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
6. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
7. How Big Is Your Brain? Its Size May Protect You from Memory Loss
8. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
9. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML